{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:30Z","timestamp":1792787790710,"version":"4.5.0"},"reference-count":16,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"name":"Oskar-Helene-Heim foundation, Berlin, Germany"},{"name":"Guenther Labes foundation, Berlin, Germany"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,10,21]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1183\/13993003.01496-2025","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:14Z","timestamp":1767864914000},"page":"2501496","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of high dose bedaquiline treatment in patients with extensively drug-resistant tuberculosis"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-9115","authenticated-orcid":false,"given":"Manuel","family":"Peterka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khatamzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4741","authenticated-orcid":false,"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Macholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-5785","authenticated-orcid":false,"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Daller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Knappik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"H\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Polsfu\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1275-7361","authenticated-orcid":false,"given":"Torsten","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Otto-Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026010801350836000_67.1.2501496.1","unstructured":"World Health Organization . WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment and Care. Geneva, World Health Organization, 2025."},{"key":"2026010801350836000_67.1.2501496.2","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026010801350836000_67.1.2501496.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00621-2021"},{"key":"2026010801350836000_67.1.2501496.4","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1016\/S2666-5247(23)00321-X","article-title":"Emerging bedaquiline-resistant tuberculosis","volume":"4","author":"Lange","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026010801350836000_67.1.2501496.5","first-page":"23","article-title":"Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis","volume":"35","author":"Gaida","year":"2020","journal-title":"S Afr J Infect Dis"},{"key":"2026010801350836000_67.1.2501496.6","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026010801350836000_67.1.2501496.7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa136"},{"key":"2026010801350836000_67.1.2501496.8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5588\/ijtldopen.23.0527","article-title":"Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment","volume":"1","author":"Lounis","year":"2024","journal-title":"IJTLD Open"},{"key":"2026010801350836000_67.1.2501496.9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jinf.2023.01.039","article-title":"Pretomanid-resistant tuberculosis","volume":"86","author":"Koehler","year":"2023","journal-title":"J Infect"},{"key":"2026010801350836000_67.1.2501496.10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(24)00186-3","article-title":"Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial","volume":"12","author":"Goodall","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026010801350836000_67.1.2501496.11","doi-asserted-by":"crossref","unstructured":"Gavras N , Schluger NW . QT prolongation associated with administration of bedaquiline, a novel anti-tuberculosis drug. Cardiol Rev 2024; in press. doi:10.1097\/CRD.0000000000000790","DOI":"10.1097\/CRD.0000000000000790"},{"key":"2026010801350836000_67.1.2501496.12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bcp.14199","article-title":"Understanding the drug exposure\u2013response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis","volume":"86","author":"Tanneau","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026010801350836000_67.1.2501496.13","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/jac\/dkx317","article-title":"Modelling of mycobacterial load reveals bedaquiline's exposure\u2013response relationship in patients with drug-resistant TB","volume":"72","author":"Svensson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026010801350836000_67.1.2501496.14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5588\/ijtldopen.25.0240","article-title":"Clinical best practices for caring for people with expanded resistance to newer TB drugs","volume":"2","author":"Nkomo","year":"2025","journal-title":"IJTLD Open"},{"key":"2026010801350836000_67.1.2501496.15","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2666-5247(23)00401-9","article-title":"Phase 2 trial of a novel tuberculosis drug launched","volume":"5","author":"Holt","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026010801350836000_67.1.2501496.16","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","article-title":"Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis","volume":"4","author":"Sonnenkalb","year":"2023","journal-title":"Lancet Microbe"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01496-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:16Z","timestamp":1767864916000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01496-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.01496-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01496-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}